Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:18 2025-12-12 am EST			5-day change	1st Jan Change
1,824.50 ^GBX	+0.19%		+1.08%	+35.50%

Dec. 12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE
Dec. 12	Surprise UK GDP Contraction Keeps FTSE 100 in the Red	MT

Press Releases

GSK'227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA	Dec. 11	AQ
GSK : data at ASH show potential to redefine outcomes for people living with blood cancers	Dec. 01	PU
GSK : TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.	Nov. 20	PU
GSK : and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology	Nov. 19	PU
GSK : presents data from its advancing liver pipeline at AASLD 2025	Nov. 07	PU
GSK : Q3 2025 results transcript	Oct. 30	PU
GSK : Q3 2025 results slides	Oct. 29	PU
GSK : Q3 2025 pipeline assets and clinical trials report	Oct. 29	PU
GSK : Q3 2025 results infographic	Oct. 29	PU
GSK : Q3 2025 US dollar translation	Oct. 29	PU
GSK : delivers strong Q3 performance and upgrades 2025 guidance	Oct. 29	PU
Glaxo: Q3 Earnings Snapshot	Oct. 29	AQ
GSK : B7-H3-targeted antibody-drug conjugate, GSK’227, receives Orphan Drug Designation in the EU	Oct. 28	PU
GSK : and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases	Oct. 28	PU
GSK : acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer	Oct. 27	PU
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma	Oct. 23	BU
GSK : Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma	Oct. 23	PU
GSK - Positive PIVOT-PO phase III data show tebipenem HBr's potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections	Oct. 22	AQ
GSK : Shingrix new prefilled syringe presentation receives positive CHMP opinion	Oct. 21	PU
GSK : Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment	Oct. 20	PU
ViiV HEALTHCARE'S CLARITY STUDY SHOWS LONG-ACTING CABOTEGRAVIR MORE ACCEPTABLE THAN LENACAPAVIR INJECTIONS AFTER A SINGLE DOSE, WITH 90% PREFERRING CABOTEGRAVIR	Oct. 16	AQ
GSK : Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression	Oct. 14	PU
GSK : Q3 2025 pre announcement aide memoire	Oct. 09	PU
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level	Oct. 01	BU
GSK to submit label update for Wellcovorin at US FDA's request	Sep. 23	AQ